Therapeutic Indications

Cinacalcet is indicated for:

Secondary hyperparathyroidism (HPT) in children with end-stage renal disease (ESRD)

Irrespective of gender only Children (1 year - 12 years old) , Adolescents (12 years - 18 years old)

Treatment of secondary hyperparathyroidism (HPT) in children aged 3 years and older with end-stage renal disease (ESRD) on maintenance dialysis therapy in whom secondary HPT is not adequately controlled with standard of care therapy.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 0.2-2.5mg/kg once per day

Secondary hyperparathyroidism (HPT) in adult patients with end-stage renal disease (ESRD)

Irrespective of gender only Adults (18 years old or older)

Cinacalcet is indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with end-stage renal disease (ESRD) on maintenance dialysis therapy.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 30-180mg once per day

Parathyroid carcinoma and primary hyperparathyroidism

Irrespective of gender only Adults (18 years old or older)

Reduction of hypercalcaemia in adult patients with:

  • Parathyroid carcinoma.
  • Primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 60-360mg in 2-4 divided doses per day

Contraindications

Active ingredient Cinacalcet is contraindicated in the following cases:

Hypocalcaemia

No gender/age discrimination